Search the Newsreel

10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect

Earnings Preview: BNGO to Report Financial Results Post-market on August 10

Bionano Genomics (BNGO) is scheduled to report its financial results on August 10 after the market closes. Analysts are anticipating a loss of $0.06 per share on revenue of $10.14 million for the quarter. This release will provide investors with an update on the …

NeoGenomics, Inc. (NEO) Hit a 52 Week High, Can the Run Continue?

NeoGenomics, Inc. (NEO) recently hit a new 52-week high, with its stock up 4.5% in the past month and 34.7% since the start of the year. This outperformance is attributed to strong earnings surprises, with expected EPS growth of 50% for the current fiscal …

NEO5107997 Bond Profile — Key Metrics

This article provides key metrics for the NEO5107997 bond issued by NeoGenomics, Inc. It details the bond's coupon rate, issue and maturity dates, outstanding amount, and face value. The profile also includes a brief description of NeoGenomics, Inc., a clinical laboratory company specializing in …

Mega Genomics Sets Board Meeting to Approve Interim Results and Consider Dividend

NeoGenomics (NEO) Following Q2 Profit And Raised Outlook, Is Fair Value Already Priced In?

NEO Stock Price and Chart — NASDAQ:NEO

This article provides a comprehensive overview of NeoGenomics, Inc. (NASDAQ: NEO), including its stock price performance, key financial metrics, recent earnings report, and analyst ratings. It highlights the company's Q2 2026 revenue growth and increased full-year guidance. The article also includes various trading ideas …

Bionano Genomics, Inc. Revenue Breakdown – NASDAQ:BNGO

Bionano Genomics, Inc. reported a total revenue of $28.51 million USD last year. The largest contributing segment was Consumables, generating $13.97 million USD, an increase from $12.77 million USD in the prior year. Geographically, the EMEA region was the primary revenue driver, contributing $14.11 …

Diluted shares outstanding of Bionano Genomics, Inc. – GETTEX:2Y3

This article provides financial information for Bionano Genomics, Inc. (GETTEX:2Y3), specifically focusing on its diluted shares outstanding. The content is presented within the TradingView platform, offering various financial data points and tools for analysis.

Net income before discontinued operations of Bionano Genomics, Inc. – GETTEX:2Y3

This page provides financial data, specifically net income before discontinued operations, for Bionano Genomics, Inc. (2Y3) listed on Gettex. The content is primarily a data placeholder within TradingView's platform, indicating no trades have occurred for this particular metric yet.

Bionano Genomics Inc (BNGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bionano Genomics Inc (BNGO), detailing its price momentum score of 3.18 and identifying current support at $1.00 and resistance at $1.16. It presents a summary of various technical indicators, such as MACD and RSI, which largely suggest …

BlackRock (NEO holder) discloses 20.4M-share NeoGenomics stake in latest update

BlackRock, Inc. has filed an amended beneficial ownership report revealing a 15.6% stake in NeoGenomics, Inc., totaling 20,358,331 shares. Of these, BlackRock holds sole voting power over 19,688,877 shares and sole dispositive power over all 20,358,331 shares. The filing also notes that the iShares …

Bionano Genomics (BNGO) CSO reports holding 63 shares

Bionano Genomics' Chief Scientific Officer, Alex Reid Hastie, has filed an initial statement of beneficial ownership (Form 3) reporting direct ownership of 63 shares of the company's common stock. This filing indicates no insider purchases or sales in this specific report. It establishes his …

First Trust entities disclose 10.1M-share NeoGenomics (NEO) position in 13G

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, disclosing beneficial ownership of 10,113,261 shares of NeoGenomics (NEo), which represents 7.77% of the class. First Trust Advisors L.P. and The Charger Corporation hold shared voting …

10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

10x Genomics, CHUV Expect Hundreds of Patients in Cancer Study

10x Genomics announced a multi-year research collaboration with Lausanne University Hospital (CHUV) to advance diagnostic applications of single cell and spatial technologies in cancer care. The study aims to identify clinically relevant biomarkers for predicting treatment response and prognosis across various solid tumors using …

NeoGenomics, Inc. Stock 12‑Month Price Target Raised to $19.72, Implies 47% Upside

Analyst estimates have led to an increased average 12-month price target for NeoGenomics, Inc. (NEO) stock, rising from $16.78 to $19.72, with a range of $16 to $35 per share. This updated target suggests a potential upside of approximately 47% from its closing price …

10x Genomics Inc Class A Revenue Breakdown – GETTEX:1KJ

This article details the revenue breakdown for 10x Genomics Inc Class A (GETTEX:1KJ). In the last fiscal year, the company generated 547.31 million EUR, with the Consumables - Single Cell segment contributing the most at 309.24 million EUR. The United States was the largest …

NeoGenomics (NEO) Stock Rallies As Profit Returns And Margins Improve

NeoGenomics (NEO) stock rallied by 14% after reporting a swing from a Q1 loss to a modest Q2 profit, driven by improved margins and increased average price per test. While clinical revenue and NGS growth are strong, concerns remain regarding the decline in pharma …

Metagenomi Inc (MGX) Valuation: PE, PB & Fair Value Analysis

Metagenomi Inc (MGX) currently has a valuation score of 8.48, placing it 118th out of 385 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -0.53, which is 5.79% below its recent high and 1178.03% above its recent low. Key valuation …

Needham raises Neogenomics stock price target on strong Q2 results

Needham has increased its price target for Neogenomics Inc. (NASDAQ:NEO) to $19.00 from $15.00, maintaining a Buy rating, following strong second-quarter 2026 results. The company surpassed revenue and EBITDA consensus estimates, leading management to raise full-year guidance and indicating a potential return to profitability …

Bionano Genomics Inc (BNGO) Financial Health: Profitability & Balance Sheet Analysis

Bionano Genomics Inc (BNGO) has a weak financial score of 5.95, ranking 180 out of 199 in its industry due to low operating efficiency. Despite this, its latest quarterly revenue increased by 3.56% year-over-year, and net profit saw a significant 167.67% year-over-year increase. The …

Neogenomics stock hits 52-week high at 15.61 USD

NeoGenomics Inc. (NEO) stock reached a 52-week high of $15.61 USD, representing a 162.75% increase over the past year. Despite trading above its Fair Value, analysts are optimistic about the company turning profitable this year. This surge follows strong second-quarter 2026 earnings, where NeoGenomics …

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics, Inc. announced its second-quarter 2026 results, showing an 11% year-over-year increase in total revenue to $202 million, with robust clinical services revenue growth of 14% driven by a 26% increase in NGS revenue. The company reported a GAAP net income of $2 million …

Gamco Investors INC. ET AL Boosts Stock Holdings in NeoGenomics, Inc. $NEO

Gamco Investors INC. ET AL significantly increased its stake in NeoGenomics, Inc. by 525% in the first quarter, now holding 100,000 shares valued at $742,000. This move comes as NeoGenomics reported better-than-expected Q2 earnings and raised its fiscal 2026 revenue guidance, despite ongoing concerns …

Bionano Genomics Inc (BNGO) Institutional Confidence

Bionano Genomics Inc (BNGO) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion increased by 354.71% quarter-over-quarter to 10.52%. James Simons is the largest institutional shareholder, holding 0.44% of …

NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

NeoGenomics Inc (NEO) reported strong Q2 2026 results with an 11% year-over-year revenue growth to $201.7 million, driven by robust clinical and Next-Generation Sequencing (NGS) performance. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance …

NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-07-28

This article announces that NeoGenomics, Inc. published its Q2 2026 earnings call presentation. The company reported an EPS of $0.05, beating estimates by $0.02, and revenue of $201.66M, surpassing expectations by $4.67M and representing an 11.21% year-over-year increase. The presentation is related to their …

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Earnings Call Insights: NeoGenomics (NEO) Q2 2026 MANAGEMENT VIEW * "We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year." (CEO Anthony Zook) * "Total revenue in the quarter was $201.7 …

NeoGenomics (NASDAQ:NEO) Posts Earnings Results, Beats Expectations By $0.02 EPS

NeoGenomics (NASDAQ:NEO) reported quarterly earnings that surpassed analyst expectations, with an EPS of $0.05 against an estimated $0.03, and revenue of $201.66 million, exceeding the $196.93 million estimate. Despite the positive earnings surprise, the company posted a negative net margin and return on equity. …

Earnings call transcript: NeoGenomics tops Q2 2026 estimates and lifts outlook

NeoGenomics Inc. reported strong second-quarter 2026 earnings, surpassing Wall Street expectations for both profit and sales, driven by robust clinical and next-generation sequencing (NGS) business growth. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, despite continued weakness in its non-clinical pharma …

Resultados trimestrales: NeoGenomics supera las previsiones con un beneficio por acción ajustado de 0,05 USD en el segundo trimestre

NeoGenomics Releases Q2 2026 Financial Results

NeoGenomics, Inc. reported strong Q2 2026 financial results, with adjusted EPS of $0.05, significantly beating analyst estimates, and revenue of $201.7M, surpassing consensus. The company saw an 11.2% increase in revenue year-over-year, primarily driven by its clinical services segment. Management provided full-year adjusted EPS …

Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) generated $25.21 million in revenue last year, with its Ionis segment contributing the most at $24.62 million. This marks a decrease from the previous year's total revenue of $30.44 million. The United States was the primary geographic contributor, accounting for …